Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development
Journal of Medicinal Chemistry2009Vol. 52(23), pp. 7360–7363
Citations Over TimeTop 10% of 2009 papers
Mark D. Wittman, Joan M. Carboni, Yang Zheng, Francis Y. Lee, Melissa Antman, Ricardo M. Attar, Praveen Balimane, ChiehYing Chang, Cliff Chen, Lorell Discenza, David B. Frennesson, Marco M. Gottardis, Ann Greer, Warren Hurlburt, Walter L. Johnson, David R. Langley, Aixin Li, Jianqing Li, Peiying Liu, Harold Mastalerz, Arvind Mathur, Krista Menard, Karishma Patel, John S. Sack, Xiaopeng Sang, Mark G. Saulnier, Daniel Smith, Kevin Stefanski, George L. Trainor, Upender Velaparthi, Guifen Zhang, Kurt Zimmermann, Dolatrai M. Vyas
Abstract
This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development.
Related Papers
- → Comparative effects of plateletderived growth factor‐BB and insulin‐like growth factor‐I, individually and in combination, on periodontal regeneration in Macaca fascicularis(1996)226 cited
- → Autocrine/paracrine mechanism of insulin‐like growth factor‐1 secretion, and the effect of insulin‐like growth factor‐1 on proteoglycan synthesis in bovine intervertebral discs(1996)207 cited
- → Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation(2010)88 cited
- → Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor – A Splice Variant of IGF-1 within the Growth Plate(2013)24 cited